BIVI

BIOVIE INC. (BIVI) - 10-Q Filing Summary

Business Context and Reporting Period

Company: BIOVIE INC.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2026
Business Overview: BioVie is a clinical-stage biopharmaceutical company developing therapies for neurological/neurodegenerative disorders (Alzheimer's, Parkinson's, Long COVID) and advanced liver disease. The company is pre-revenue and relies on equity financing and grants to fund operations.

Key Financial Metrics

Cash Flow (Nine Months Ended Mar 31, 2026):
- Net cash used in operating activities: $(14.90) million
- Net cash provided by financing activities: $10.46 million (primarily from equity issuance)
- Net decrease in cash: $(4.45) million

Material Changes vs. Prior Period

• Net Loss Increase: Net loss for the nine months ended March 31, 2026, increased by approximately $2.37 million compared to the prior year period ($14.05 million). This was driven by a $2.53 million increase in operating expenses.
• R&D Expenses: Increased by $2.34 million year-over-year (nine months) to $10.38 million. The increase is attributed to the full enrollment and progression of the Sunrise PD Phase 2 study and the Long COVID Phase 2 study.
• Grant Reimbursements: Recognized approximately $4.1 million in grant reimbursements for the nine months ended March 31, 2026, compared to $2.9 million in the prior year, partially offsetting R&D costs.
• Capital Raise: In August 2025, the company completed an underwritten public offering raising approximately $10.5 million in net proceeds, issuing 5.62 million units and 380,000 pre-funded units.
• Stock-Based Compensation: Significant increase in stock-based compensation expense, particularly for stock options ($2.03 million for the nine months ended Mar 31, 2026 vs. $0.84 million prior year), due to new grants to directors and employees.

Outlook, Risks, and Contingencies

• Clinical Milestones:
  • Parkinson's Disease: The Phase 2b "Sunrise" study enrolled 60 patients by December 2025. Topline results are expected in mid-2026.
  • Long COVID: The Phase 2 ADDRESS-LC study commenced in May 2025. As of March 31, 2026, total costs incurred were ~$9.4 million, with ~$9.4 million reimbursed by the DOD grant.
  • Liver Cirrhosis: Finalizing Phase 3 protocol for BIV201 (terlipressin) targeting patients with ascites and recent acute kidney injury.
• Liquidity & Going Concern: Management states there is "substantial doubt" about the company's ability to continue as a going concern without additional financing. Future operations depend on successful clinical outcomes and the ability to raise capital.
• Legal Proceedings:
  • Securities Class Action: In re BioVie Inc. Securities Litigation alleges misrepresentations regarding the NM101 Phase 3 study. The court denied the motion to dismiss in March 2025; fact discovery is ongoing. A motion for class certification is pending.
  • Derivative Lawsuits: Three consolidated shareholder derivative lawsuits are stayed pending the resolution of the class action.
• Dilution Risk: As of March 31, 2026, there were 7.9 million warrants and 2.8 million stock options outstanding, creating significant potential dilution.

Investor Verification Checklist

• Cash Runway: Verify the current cash burn rate against the $13.1 million cash balance to determine the runway before the next capital raise is required.
• Grant Reimbursement Timing: Confirm the timing of future DOD grant reimbursements for the Long COVID study, as cash flow is heavily dependent on these inflows.
• Legal Exposure: Monitor the status of the securities class action and derivative lawsuits, specifically the outcome of the class certification motion due June 15, 2026.
• Clinical Data: Await the mid-2026 topline results of the Parkinson's Phase 2b study, which is a critical value driver.
• Dilution Impact: Assess the impact of the 7.9 million outstanding warrants and potential future equity issuances on existing shareholder value.